Key result
HostSeq integrates whole genome and clinical data to support COVID-19 genetic risk research.
Why the study?
Integration of whole genome sequencing data with clinical information from Canadians infected with SARS-CoV-2 was needed to support research on disease risk factors and outcomes.
Answers are grounded in this paper and cite their sources.
Expands Canadian resources for COVID-19 genetic studies; leaves open clinical translation of any identified variants.
HostSeq was launched in April 2020 as a national initiative to integrate whole genome sequencing data from 10,000 Canadians infected with SARS-CoV-2 with clinical information related to their disease experience. The mandate of HostSeq is to support the Canadian and international research communities in their efforts to understand the risk factors for disease and associated health outcomes and support the development of interventions such as vaccines and therapeutics. HostSeq is a collaboration among 13 independent epidemiological studies of SARS-CoV-2 across five provinces in Canada. Aggregated data collected by HostSeq are made available to the public through two data portals: a phenotype portal showing summaries of major variables and their distributions, and a variant search portal enabling queries in a genomic region. Individual-level data is available to the global research community for health research through a Data Access Agreement and Data Access Compliance Office approval. Here we provide an overview of the collective project design along with summary level information for HostSeq. We highlight several statistical considerations for researchers using the HostSeq platform regarding data aggregation, sampling mechanism, covariate adjustment, and X chromosome analysis. In addition to serving as a rich data source, the diversity of study designs, sample sizes, and research objectives among the participating studies provides unique opportunities for the research community.
No takes yet. Share an insight, caveat, or question.
Yoo et al. (2023) studied SARS-CoV-2 infection (n=9,427). Whole genome sequencing and clinical data integration was evaluated. HostSeq successfully integrated whole genome sequencing and clinical data from 9,427 Canadians infected with SARS-CoV-2 to support research into genetic risk factors for COVID-19 outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: